10x Genomics, Inc.: Form 10-Q for the period ended Mar 31, 2023
Filed with the SEC on May 4, 2023 and accepted by EDGAR at May 4, 2023, 17:04 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-01-01 to 2023-03-31 | $134.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-01-01 to 2023-03-31 | $35.9m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2023-01-01 to 2023-03-31 | $98.4m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2023-01-01 to 2023-03-31 | $83.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-01-01 to 2023-03-31 | −$52.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-01-01 to 2023-03-31 | $19.0k | us-gaap:InterestExpense |
| Income tax | 3 months2023-01-01 to 2023-03-31 | $1.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-01-01 to 2023-03-31 | −$50.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-01-01 to 2023-03-31 | −$0.44 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-01-01 to 2023-03-31 | −$0.44 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-01-01 to 2023-03-31 | 115,619,869 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2023-01-01 to 2023-03-31 | −$4.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2023-01-01 to 2023-03-31 | $4.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Current assets | At period end2023-03-31 | $601.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-03-31 | $1.01bn | us-gaap:Assets |
| Current liabilities | At period end2023-03-31 | $112.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-03-31 | $211.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-03-31 | $802.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001770787-23-000029. Last ingested by Listed: Nov 6, 2026, 17:47 ET. Listed shows no prices and gives no investment advice.